Novo Nordisk, Sable Offshore, StoneCo And Other Big Stocks Moving Higher On Tuesday

Benzinga · 12/23/2025 15:15
U.S. stocks were lower, with the Dow Jones index falling around 0.1% on Tuesday.
Shares of Novo Nordisk A/S (NYSE:NVO) rose sharply during Tuesday's session following FDA approval of its Wegovy pill.
Novo Nordisk received approval from the U.S. Food and Drug Administration for its GLP-1 pill, marking the first approval of its kind globally.
Novo Nordisk shares jumped 8.6% to $52.26 on Tuesday.
Here are some other big stocks recording gains in today’s session.
- WW International Inc (NASDAQ:WW) shares jumped 14.4% to $30.42. Weight Watchers recently launched an integrated GLP-1 program.
- Lifezone Metals Ltd (NYSE:LZM) gained 11.1% to $4.43.
- Hycroft Mining Holding Corporation (NASDAQ:HYMC) gained 9.1% to $26.75.
- Sable Offshore Corp (NYSE:SOC) gained 8.8% to $8.27 after the company said the US Pipeline and Hazardous Materials Safety Administration approved the restart plans for the Las Flores Pipeline system.
- Ascentage Pharma Group International (NASDAQ:AAPG) gained 8.4% to $28.17.
- Lionsgate Studios Corp (NYSE:LION) shares surged 8.3% to $9.06. Lionsgate Studios recently expanded access to its ad-supported streaming inventory.
- Critical Metals Corp (NASDAQ:CRML) gained 7.6% to $8.65.
- ZIM Integrated Shipping Services Ltd (NYSE:ZIM) shares rose 7.4% to $21.35 after the company said it received proposals from multiple parties to acquire all outstanding shares and is currently evaluating the offers.
- mF International Limited (NASDAQ:MFI) gained 7.1% to $21.38.
- Intrepid Potash Inc (NYSE:IPI) shares rose 7.1% to $29.06.
- Sellas Life Sciences Group Inc (NASDAQ:SLS) gained 6.8% to $2.82.
- StoneCo Ltd (NASDAQ:STNE) gained 5.8% to $14.96. StoneCo’s board authorized a new share repurchase program, under which Stone may repurchase up to R$2 billion in outstanding Class A common shares.
- Century Aluminum Co (NASDAQ:CENX) rose 5% to $39.02. Wells Fargo analyst Timna Tanners maintained Century Aluminum with an Overweight rating and raised the price target from $37 to $46.
Read This Next:
Photo via Shutterstock
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.